Reducing Concurrent Opioid-Benzodiazepine Prescriptions

Category Primary study
Registry of Trialsclinicaltrials.gov
Year 2019
The purpose of this effort is to use low‐cost informative e‐mails to improve the process of prescribing of opioids and benzodiazepines within the National Capital Region/Military Health System (NCR/MHS), with the aim of decreasing concurrent opioid and benzodiazepine prescribing. Both the VA/DoD Clinical Practice Guideline for Opioid Therapy for Chronic Pain (2017) and the CDC Guideline for Prescribing Opioids for Chronic Pain (2016) strongly recommend against the concurrent use of opioids and benzodiazepines. Taken together, these drugs could cause respiratory depression, enhanced sedation, and death. The intervention population will be prescribers and primary care managers associated with patients who have recently received concurrent prescriptions of opioids and benzodiazepines. Using a randomized approach, we will allocate the NCR/MHS providers associated with patients with concurrent prescriptions for opioids and benzodiazepines to one of two conditions: 1. E‐mail alert ‐ A messaging approach, in which we will send encrypted emails to the patient's opioid and benzodiazepine prescriber(s) and primary care manager that identify the concurrent prescriptions and detail the patient's prescription history, inform them of the VA/DoD guideline and risk to patient, and provide action steps and relevant resources. When multiple providers are involved, the email message will also encourage coordination across providers and provide relevant contact information 2. As‐Usual ‐ An as‐usual approach, in which providers are not sent messages. These providers can access patient information through the MHS Opioid Registry as before.
Epistemonikos ID: e64699f891b1fe5a50172295da95f36c468adf12
First added on: May 22, 2024